Dr. Balcer’s primary research focus is on the identification and development of clinical visual outcome measures for multiple sclerosis (MS) trials. Dr. Balcer’s group, funded jointly by the National Eye Institute and the National MS Society, focuses on determining which clinical tests best identify visual dysfunction in patients with MS. These studies have also examined the relation of visual function to neurologic impairment, magnetic resonance imaging abnormalities, and health-related quality of life. Data from these and other investigations at U. Penn have led to the inclusion of low-contrast letter acuity as a secondary outcome measure in 2 international MS treatment trials. A new ocular imaging technique, optical coherence tomography (OCT), has been used to examine retinal nerve fiber layer and macular thickness as biologic markers of neuronal and axonal loss in patients with MS.
Neuro-Ophthalmology; Neuro-Ophthalmologic features of multiple sclerosis (MS)
Ventura RE, Galetta SL, Balcer LJ: The neuro-ophthalmology of head trauma. Lancet Neurol 13: 1006-1013, 2014.
Balcer LJ, Galetta SL: OCT and NMO: are there methods to our madness? J Neuro-Ophthalmol 33: 209-12, 2013.
Fisher M.J., Loguidice M., Gutman D.H., Listernick R., Ferner R.E., Ullrich N.J., Packer R.J., Tabori U., Hoffman R.O., Ardern-Holmes S.L., Hummel T.R., Hargrave D.R., Bouffet E., Charrow J., Bilaniuk L.T., Balcer L.J., Liu G.T. : Visual outcomes in children with neurofibromatosis type 1 - associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro-Oncology 14: 790-797, 2012.
Balcer L.J., Galetta S.L., Polman C.H., Eggenberger E., Calabresi P.A., Zhang A., Scanlon J.V., Hyde R. : Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS. Journal of the Neurological Sciences 318: 119-124, 2012.
Moss H.E., McCluskey L., Elman L., Hoskins K., Talman L., Grossman M., Balcer L.J., Galetta S.L., Liu G.T. : Cross-sectional evaluation of clinical neuro-ophthalmic abnormalities in an amyotrophic lateral sclerosis population. Journal of the Neurological Sciences 314: 97-101, 2012.
Walter S.D., Ishikawa H., Galetta K.M., Sakai R.E., Feller D.J., Wilson J.A., Maguire M.G., Galetta S.L., Frohman E.M., Calabresi P.A., Schuman J.S., Balcer L.J.: Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology 119: 1250-1257, 2012.
Galetta K.M., Graves J., Talman L.S., Lile D.J., Frohman E.M., Calabresi P.A., Galetta S.L., Balcer L.J.: Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study. Journal of Neuro-Ophthalmology 32: 116-123, 2012.
Davies E.C., Henderson S., Balcer L.J., Galetta S.L.: The King-Devick test and sleep deprivation: study in pre- and post-call neurology residents. Neurology 78: e103-106, 2012.
Ontaneda D, LaRocca N, Coetzee T, Rudick R: NMSS MSFC Task Force. Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society(NMSS) Task Force on Clinical Disability Measures. Mult Scler 18: 1074-80, 2012.
Levin M.H., Ney J.J., Venneti S., Moster M.L., Balcer L.J., Volpe N.J., Gausas R.E., Liu G.T., Vagefi M.R., Galetta S.L.: Optic nerve biopsy in the management of progressive optic neuropathy. Journal of Neuro-Ophthalmology 2012.
back to top
Last updated: 11/17/2014
The Trustees of the University of Pennsylvania